[Anti-inflammation of simvastatin by polarization of murine macrophages from M1 phenotype to M2 phenotype].
Quanzhong Li, Jing Sun, Jinjie Han, Zongjie Qian
Abstract
Quanzhong Li, Jing Sun, Jinjie Han, Zongjie Qian
Abstract
OBJECTIVE: To explore the effects of statin on pro-inflammatory macrophage phenotype in a murine M1 macrophage model. METHODS: Macrophages isolated from murine bone barrow were stimulated with interferon-gamma (IFN-γ) and lipopolysaccharide (LPS) to establish a M1 macrophage model. And 1.0, 2.5, 5.0 µmol/L of simvastatin were added to M1 macrophages for a 9-hour culture. Cell surface markers CD16/23 and CD206 were detected by fluorescence activated cell sorter (FACS) and interleukin-10 (IL-10) and IL-12 by ELISA. RESULTS: The CD16/32 expression was 86.39% ± 2.24% and IL-12 secretion (1562 ± 217) pg/ml in IFN-γ and LPS-stimulated macrophages. After a 9-hour incubation with 1.0, 2.5, 5.0 µmol/L simvastatin, the CD206 expression levels were 68.10% ± 2.48%, 75.28% ± 1.66%, 86.32% ± 2.19% and the secretion of IL-10 (500 ± 5), (675 ± 28) and (916 ± 15) pg/ml respectively. By analysis of variance and q test of mean, the difference was statistically significant (all P < 0.01) between the groups of M1 model (9.67% ± 5.48%, (298 ± 11) pg/ml) . And the phenotypic features were similar to those of the groups of M2 model. CONCLUSION: Simvastatin may inhibit inflammation by enhancing the switching of M1 macrophage to M2 macrophage phenotype.
OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: To explore the effects of statin on pro-inflammatory macrophage phenotype in a murine M1 macrophage model. METHODS: Macrophages isolated from murine bone barrow were stimulated with interferon-gamma (IFN-γ) and lipopolysaccharide (LPS) to establish a M1 macrophage model. And 1.0, 2.5, 5.0 µmol/L of simvastatin were added to M1 macrophages for a 9-hour culture. Cell surface markers CD16/23 and CD206 were detected by fluorescence activated cell sorter (FACS) and interleukin-10 (IL-10) and IL-12 by ELISA. RESULTS: The CD16/32 expression was 86.39% ± 2.24% and IL-12 secretion (1562 ± 217) pg/ml in IFN-γ and LPS-stimulated macrophages. After a 9-hour incubation with 1.0, 2.5, 5.0 µmol/L simvastatin, the CD206 expression levels were 68.10% ± 2.48%, 75.28% ± 1.66%, 86.32% ± 2.19% and the secretion of IL-10 (500 ± 5), (675 ± 28) and (916 ± 15) pg/ml respectively. By analysis of variance and q test of mean, the difference was statistically significant (all P < 0.01) between the groups of M1 model (9.67% ± 5.48%, (298 ± 11) pg/ml) . And the phenotypic features were similar to those of the groups of M2 model. CONCLUSION: Simvastatin may inhibit inflammation by enhancing the switching of M1 macrophage to M2 macrophage phenotype.
Key concepts: Simvastatin, Macrophage, Lipopolysaccharide, Macrophage polarization, Inflammation, CD16, Phenotype, M2 Macrophage